Association between use of antacid medications (proton pump inhibitors and histamine-2 receptor antagonists) and the incidence of lung cancer: A population-based cohort analysis. Issue 36 (9th September 2022)

• Record Type: Journal Article
• Authors: Go, Subin; Lee, Dong Yoon; Choi, Won-Il; Jeong, Jihyeon
• Is Part Of: Medicine. Volume 101:Issue 36(2022)
• Page Start: e30399
• Publication Date: 2022-09-09
• Subjects: antacid -- incidence -- lung cancer; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000030399
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : This study investigated the association between antacid administration and lung cancer incidence in a real-world setting. This was a nationwide, retrospective cohort study. The cohort comprised random samples (n = 1, 031, 392) from the entire South Korean population in 2002. The duration of antacid administration between January 2006 and December 2010 was recorded for each participant. Newly developed lung cancers were counted during the 5-year observation period (January 1, 2006 to December 31, 2010). A total of 437, 370 participants aged ≥ 40 years were included, of whom 301, 201 (68.9%) had antacid exposure before the diagnosis of lung cancer. A total of 1230 (0.28%) antacid-exposed patients developed lung cancer. Among patients with no antacid exposure or underexposure (n = 136, 171), 597 (0.44%) developed lung cancer. In the multivariable analysis, antacid exposure before the diagnosis of lung cancer was independently associated with a reduced incidence of lung cancer (hazard ratio: 0.64; 95% confidence interval: 0.55–0.74; P < .001). Antacid use might be independently associated with a decreased risk of lung cancer development in this cohort study.